PrimeRFP SCOUT · Federal Contract Recompete Brief

W911QY21D0012Covid-19 combination monoclonal antibody — Eli Lilly and Company

Eli Lilly and Company holds $282K across 4 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award in the incumbent pipeline. Set-aside status: Unrestricted.

W6qk Acc-Apg Natick
Awarding office
Eli Lilly and Company
Recipient
—
Estimated value
6505
PSC
Unrestricted
Set-aside

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted
Contract numberW911QY21D0012
Also listed asW911QY-21-D-0012
AgencyW6qk Acc-Apg Natick
Awarding officeW6qk Acc-Apg Natick
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentEli Lilly and Company
UEIUHHVNTY54K68
PSC6505

COVID-19 COMBINATION MONOCLONAL ANTIBODY is a federal Unrestricted award for W6qk Acc-Apg Natick held by Eli Lilly and Company. Estimated value —.

Bonuses end Sept 30

Want the durability read on W911QY21D0012? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Eli Lilly and Company — $282K obligated across 4 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)
Department of Veterans Affairs (VA)$282K · 100% of firm total
Open full company profile →

Related awards

Same incumbent
36C25026N0080
AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN
$230K
Oct 5, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract W911QY21D0012?

W911QY21D0012 (Covid-19 combination monoclonal antibody) is a W6qk Acc-Apg Natick award with an estimated value of —, currently held by Eli Lilly and Company. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W911QY-21-D-0012?

W911QY-21-D-0012 is the dashed form of PIID W911QY21D0012 (Covid-19 combination monoclonal antibody), held by Eli Lilly and Company. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W911QY21D0012?

W6qk Acc-Apg Natick awarded W911QY21D0012 to Eli Lilly and Company.

Who is the incumbent on W911QY21D0012?

Eli Lilly and Company is the incumbent with $282K across 4 related awards in SCOUT’s public footprint.

When does Eli Lilly and Company’s W911QY21D0012 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on W911QY21D0012? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W911QY21D0012